Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Biotherapy
Published in: Biotherapy 4/1998

01-12-1998

The use of BRM-activated killer cells in adoptive immunotherapy: A pilot study with nine advanced cancer patients

Authors: Takusaburo Ebina, Yoshiaki Fujimiya, Tomohiro Yamaguchi, Naoko Ogama, Hiroko Sasaki, Noriko Isono, Youichi Suzuki, Ryuichi Katakura, Kazuya Tanaka, Kinya Nagata, Shoichi Takano, Keiji Tamura, Kazuko Uno, Tsunataro Kishida

Published in: Biotherapy | Issue 4/1998

Login to get access
Metadata
Title
The use of BRM-activated killer cells in adoptive immunotherapy: A pilot study with nine advanced cancer patients
Authors
Takusaburo Ebina
Yoshiaki Fujimiya
Tomohiro Yamaguchi
Naoko Ogama
Hiroko Sasaki
Noriko Isono
Youichi Suzuki
Ryuichi Katakura
Kazuya Tanaka
Kinya Nagata
Shoichi Takano
Keiji Tamura
Kazuko Uno
Tsunataro Kishida
Publication date
01-12-1998
Publisher
Kluwer Academic Publishers
Published in
Biotherapy / Issue 4/1998
Print ISSN: 0921-299X
Electronic ISSN: 1573-8280
DOI
https://doi.org/10.1023/A:1008047628284

Other articles of this Issue 4/1998

Biotherapy 4/1998 Go to the issue

OriginalPaper

Cytokine effect on ex vivo expansion of haemopoietic stem cells from different human sources

OriginalPaper

EIevated serum level of Thioredoxin in patients with Hepatocellular Carcinoma

OriginalPaper

Levamisole and Interleukin-2 for advanced malignancy

OriginalPaper

Low dose Oral Interferon Alpha 2a in HIV-1 Seropositive Patients: A Double-blind, Placebo-controlled Trial

OriginalPaper

Contribution of cytokines on the suppression of lung metastasis

OriginalPaper

Effect of herbal therapy on herpes labialis and herpes genitalis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits